Nemonapride | Emilace | YM-09151-2 | CAS#93664-94-9 | Dopamine D2/D3/D4 Receptor Antagonist

MedKoo Cat#: 328508 | Name: Nemonapride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nemonapride, also known as YM-09151-2 and Emilace, is a dopamine D2/D3/D4 receptor antagonist for the treatment of schizophrenia.

Chemical Structure

Nemonapride

CAS#93664-94-9

Theoretical Analysis

MedKoo Cat#: 328508

Name: Nemonapride

CAS#: 93664-94-9

Chemical Formula: C21H26ClN3O2

Exact Mass: 387.1714

Molecular Weight: 387.91

Elemental Analysis: C, 65.02; H, 6.76; Cl, 9.14; N, 10.83; O, 8.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Nemonapride; YM-09151-2; YM091512; YM 09151 2; Emilace

IUPAC/Chemical Name

N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide

InChi Key

KRVOJOCLBAAKSJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)

SMILES Code

O=C(NC1C(C)N(CC2=CC=CC=C2)CC1)C3=CC(Cl)=C(NC)C=C3OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 387.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Assié MB, Consul-Denjean N, Koek W, Newman-Tancredi A. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology. 2005 Oct;75(2):63-8. Epub 2005 Jul 11. PubMed PMID: 16020947. 2: Noda-Saita K, Matsumoto M, Hidaka K, Hatanaka K, Ohmori J, Okada M, Yamaguchi T. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex. Biochem Biophys Res Commun. 1999 Feb 16;255(2):367-70. PubMed PMID: 10049714. 3: Prinssen EP, Kleven MS, Koek W. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties. Eur J Pharmacol. 1998 Sep 4;356(2-3):189-92. PubMed PMID: 9774248. 4: Helmeste DM, Tang SW, Li M, Fang H. Multiple [3H]-nemonapride binding sites in calf brain. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):17-21. PubMed PMID: 9228185. 5: Nagasaki T, Ohkubo T, Sugawar K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):293-8. PubMed PMID: 9766869. 6: Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W Jr, Potkin S, Jones EG. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains. Brain Res. 1997 Aug 8;765(1):7-12. PubMed PMID: 9310388. 7: Kuribara H. Effects of sulpiride and nemonapride, benzamide derivatives having distinct potencies of antagonistic action on dopamine D2 receptors, on sensitization to methamphetamine in mice. J Pharm Pharmacol. 1996 Mar;48(3):292-6. PubMed PMID: 8737056. 8: Kondo T, Ishida M, Tokinaga N, Mihara K, Yasui-Furukori N, Ono S, Kaneko S. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):287-91. PubMed PMID: 11817505. 9: Assié MB, Cosi C, Koek W. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol. 1997 Sep 10;334(2-3):141-7. PubMed PMID: 9369342. 10: Kondo T, Mihara K, Yasui N, Nagashima U, Ono S, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Otani K. Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. J Clin Psychopharmacol. 2000 Aug;20(4):404-9. PubMed PMID: 10917400.